Loading...
XPARAB
Market cap53mUSD
Dec 23, Last price  
0.88EUR
1D
-3.39%
1Q
-15.90%
Jan 2017
-93.55%
IPO
-93.04%
Name

AB Science SA

Chart & Performance

D1W1MN
XPAR:AB chart
P/E
—
P/S
52.64
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.54%
Rev. gr., 5y
-10.63%
Revenues
970k
+1.25%
316,000917,0001,104,0001,340,0001,933,0002,099,0002,284,0001,508,0001,739,0001,701,0001,571,0001,583,0001,607,000958,000970,000
Net income
-10m
L-26.20%
-8,110,000-9,489,000-9,651,000-10,985,000-14,611,000-16,112,000-26,716,000-27,696,000-27,122,000-26,061,000-21,748,000-15,045,000-14,463,000-13,615,000-10,048,000
CFO
-17m
L-3.43%
-7,766,000-7,863,000-8,320,000-6,211,000-12,835,000-14,158,000-23,155,000-33,520,000-22,896,000-26,792,000-15,156,000-13,511,000-17,178,000-17,471,000-16,871,000
Earnings
May 13, 2025

Profile

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
URL
https://www.ab-science.com/
IPO date
Apr 21, 2010
Employees
103
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
970
1.25%
958
-40.39%
1,607
1.52%
Cost of revenue
12,700
15,531
15,415
Unusual Expense (Income)
NOPBT
(11,730)
(14,573)
(13,808)
NOPBT Margin
Operating Taxes
1,000
4
36
Tax Rate
NOPAT
(11,731)
(14,577)
(13,844)
Net income
(10,048)
-26.20%
(13,615)
-5.86%
(14,463)
-3.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,474
4
4,155
BB yield
Debt
Debt current
2,113
4,664
629
Long-term debt
17,491
20,351
9,137
Deferred revenue
Other long-term liabilities
10,929
17,139
19,264
Net debt
13,454
17,672
978
Cash flow
Cash from operating activities
(16,871)
(17,471)
(17,178)
CAPEX
(345)
(644)
(564)
Cash from investing activities
(614)
(360)
(590)
Cash from financing activities
16,274
16,391
5,844
FCF
(11,251)
(14,252)
(13,611)
Balance
Cash
6,066
7,269
8,721
Long term investments
84
74
67
Excess cash
6,102
7,295
8,708
Stockholders' equity
(286,939)
(269,597)
(257,122)
Invested Capital
295,868
274,487
261,155
ROIC
ROCE
EV
Common stock shares outstanding
68,200
47,139
47,521
Price
Market cap
EV
EBITDA
(9,459)
(14,654)
(12,077)
EV/EBITDA
Interest
3,960
2,016
1,285
Interest/NOPBT